A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Raffael Nachbagauer, Jodi Feser, Abdollah Naficy, +30

Nature Medicine

VaccinationCross-protectionVaccine DevelopmentVaccine TargetImmunology +8

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

David I. Bernstein, Jeffrey T. Guptill, Abdollah Naficy, +35

The Lancet Infectious Diseases

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Weina Sun, Yonghong Liu, Fatima Amanat, +22

Nature Communications

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

Weina Sun, Sarah R. Leist, Stephen McCroskery, +10

EBioMedicine

VaccinationSpike ProteinImmunologyViral PathogenesisVirology +4

Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model

Megan E. Ermler, Ericka Kirkpatrick, Weina Sun, +5

Journal of Virology

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Weina Sun, Stephen McCroskery, Wen‐Chun Liu, +13

Vaccines

Membrane-anchored SpikeViral PathogenesisImmunologyMembrane-anchored FormViral Structural Protein +14

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance

Sean Liu, Mohammad Amin Behzadi, Weina Sun, +9

Journal of Clinical Investigation

VaccinationVeterinary VaccineInfluenza Virus HemagglutininHi Active AntibodiesHi Profiles +12

Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach

Weina Sun, Ericka Kirkpatrick, Megan E. Ermler, +4

Journal of Virology

A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains

Felix Broecker, Sean Liu, Nungruthai Suntronwong, +5

npj Vaccines

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, +44

EClinicalMedicine